cyclacel.com (BGMS) - Cash Funds per Single Share

Corporate emblem and logo of Cyclacel (BGMS)

Bio Green Med Solution Inc is attracting leading scientists to develop targeted therapies, leveraging agile management and stock option programs. The cash per share trend illustrates financial stability, with the value of 0.52 serving as the current metric. Business valuation growth depends on the success of Fadracyclbine, while binary portfolio risks are mitigated through the use of contract research.

cyclacel.com (BGMS) - Cash per Single Share from 09/13/2025 to 11/20/2026

Comprehensive metric breakdowns and analytics for Cyclacel (BGMS)

- cash position and cash flow details:
Comprehensive company analysis:Cyclacel Pharmaceuticals - BGMS
Flagship merchandise of Cyclacel Pharmaceuticals

Investors constantly balance potential profit against the risk of capital loss. This indicator compares liquid reserve volumes with the number of shares to determine the "cash cushion" per share. By analyzing the cash-per-share structure, one can assess the issuer's financial resilience to market shocks. For Bio Green Med Solution Inc (BGMS), this reserve is critical, as the development of kinase inhibitors requires massive expenditures prior to the completion of clinical trials. A decline in this metric signals a reduction in resources available to bring drugs to market.